Table 1.
Characteristics of clinical and molecular in this study.
| Characteristics | II-III grade (IDH wild-type) | Primary GBM (IDH wild-type) | P value |
|---|---|---|---|
| Total | 165 (42.4%) | 224 (56%) | NA |
| Age | 42 (18-74) | 51 (18-79) | <0.01 |
| Gender | 0.296 | ||
| Male | 99 (60.0%) | 146 (65.2%) | |
| Female | 66 (40.0%) | 78 (34.8) | |
| Resection | 0.018 | ||
| Total resection | 77 (46.7%) | 135 (60.3%) | |
| Subtotal resection | 74 (44.8%) | 78 (34.8%) | |
| NA | 14 (8.5%) | 11 (4.9%) | |
| Tumor location | 0.264 | ||
| Multi lobe | 56 (33.9%) | 74 (33.0%) | |
| Single lobe | 78 (47.3%) | 79 (35.3%) | |
| NA | 31 (18.8%) | 71 (31.7%) | |
| Symptom | <0.001 | ||
| Seizure | 82 (49.7%) | 50 (22.3%) | |
| No seizure | 69 (41.8%) | 153 (68.3%) | |
| NA | 14 (8.5%) | 21 (9.4%) | |
| Radiotherapy | 0.072 | ||
| Yes | 134 (81.2%) | 190 (84.8%) | |
| No | 27 (16.4%) | 22 (9.8%) | |
| NA | 4 (2.4%) | 12 (5.4%) | |
| Chemotherapy | <0.001 | ||
| Yes | 80 (48.5%) | 159 (71.0%) | |
| No | 78 (47.3%) | 56 (25.0%) | |
| NA | 7 (4.2%) | 9 (4%) | |
| Median PFS (Mo) | 44 | 9.767 | <0.001 |
| Median OS (Mo) | 55 | 14.83 | <0.001 |
| 1p/19q codeletion | NA | ||
| Yes | 0 (0%) | 0 (0%) | |
| No | 51 (30.9%) | 106 (47.3%) | |
| NA | 114 (69.1%) | 118 (52.7%) | |
| MGMT methylation | 0.520 | ||
| Yes | 25 (15.2%) | 69 (30.8%) | |
| No | 42 (25.5%) | 140 (62.5%) | |
| NA | 98 (59.4%) | 15 (6.7%) | |
| PETN | 0.010 | ||
| Yes (wild) | 88 (53.3%) | 79 (35.3%) | |
| No (mutant) | 8 (5.0%) | 26 (11.6%) | |
| NA | 69 (41.7%) | 119 (53.1%) | |
| P53 | 0.518 | ||
| Yes (wild) | 87 (52.7%) | 88 (39.3%) | |
| No (mutant) | 13 (7.9%) | 17 (7.6%) | |
| NA | 65 (39.4%) | 119 (53.1%) | |
| TERT | 0.991 | ||
| Mutant | 12 (7.3%) | 22 (9.8%) | |
| Wild | 17 (10.3%) | 31 (13.8%) | |
| NA | 136 (82.4%) | 171 (76.4%) | |
| EGFR | 0.204 | ||
| Amplification | 7 (4.2%) | 14 (6.3%) | |
| Wild | 125 (75.8%) | 138 (61.6%) | |
| NA | 33 (20%) | 72 (32.1%) |